HOME

EMERGENCY USE AUTHORIZATION VACCINES

ORDER NOW!

MOQ: 1,000,000 doses (1 vial has 5 doses)
Payment Terms: 100% Irrevocable Letter of Credit
Lead time: 10 days, Origin: U.S.A. – CIF Price

Based on evidence from trials of people 16 years and older, the vaccine was 95% effective at preventing laboratory-confirmed infection with the virus that causes COVID-19 in people who received two doses and had no evidence of being previously infected.

In a clinical trial, the Pfizer-BioNTech vaccine was also highly effective at preventing laboratory-confirmed iCOVID-19 infection in people 12-15 years old, and the immune response in people 12-15 years old was at least as strong as the immune response in 16-25 years old.

The vaccine was also highly effective in clinical trials at preventing COVID-19 among people of diverse ages, sex, race, and ethnicity categories and among people with underlying medical conditions.

Evidence shows mRNA COVID-19 vaccines offer similar protection in real-world conditions as they have in clinical trials settings reducing the risk of COVID-19m including severe illness by 90% or more, among people who are fully vaccinated.

  • General Information
  • Name: BNT162b2
  • Manufacturer: Pfizer, Inc., and BioNTech
  • Type of Vaccine: mRNA
  • Number of Shots: 2 shots, 21 days apart
  • Some Immunocompromised people should get 3 shots
  • How Given: Shot in the muscle of the upper arm
  • Does NOT Contain: Eggs, preservatives, latex, metals

MOQ: 1,000,000 doses (1 vial has 5 doses)
Payment Terms: 100% Irrevocable Letter of Credit
Lead time: 7 days, EXW: Moscow, Saint Petersburg, Astana

The Sputnik V vaccine, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia and became the world’s first registered vaccine against coronavirus. Sputnik V is already registered in 60 countries.

Sputnik V is based on a safe and tested human adenovirus vector platform. Using two different human adenoviral vectors is a unique approach that allows to boost the immune response and provide long-lasting immunity.

The efficacy of the Sputnik V vaccine is confirmed at 91.6% based on the analysis of data on 19,866 volunteers, who received both the first and second doses of the Sputnik V vaccine or placebo at the final control point of 78 confirmed COVID-19 cases.

The vaccine can be stored at a temperature of +2 to +8 degrees Celsius, which allows for easy distribution worldwide, including hard-to-reach regions.

TWO – VECTOR VACCINE AGAINST CORONAVIRUS

ADVANTAGES OF PRIME-BOOST IMMUNIZATION APPROACH

MOQ: 1,000,000 doses (1 vial has 5 doses)
Payment Terms: 100% Irrevocable Letter of Credit
Lead time: 7 days, EXW: Moscow, Saint Petersburg, Astana

Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik V – the world’s first registered vaccine against coronavirus.

The Sputnik Light vaccine, like Sputnik V, is based on a proven well-studied human adenovirus vector platform; these vectors cause the common cold and have plagued humanity for millennia.

The single-dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program between 5 December 2020 and 15 April 2021.

An efficacy level of almost 80% is higher than that of many two-dose vaccines.

Sputnik Light has proven effective against all new strains of coronavirus, as demonstrated by the Gamaleya Center during laboratory tests.

MOSCOW, Aug 18 (Reuters) – Russia’s single-dose Sputnik Light vaccine against COVID-19 has demonstrated 93.5% efficacy in Paraguay, with data taken from the South American country’s vaccination the campaign, the Russian Direct Investment Fund (RDIF) said.

  • Efficacy ~80%
  • Effective against all mutations
  • 100% Protection against severe cases
  • Stored at +2 – +8 °C

MOQ: 1,000,000 doses (1 vial has 5 doses)
Payment Terms: 100% Irrevocable Letter of Credit
Lead time: 14 days or less, Origin: United Kingdom – CIF Price

 

J&J: Covid-19 vaccine Authorized by U.S. FDA For Emergency Use

The Company’s COVID-19 vaccine leverages the AdVac® vaccine platform, a unique and proprietary technology that was also used to develop and manufacture Janssen’s European Commission-approved Ebola vaccine regimen and construct its investigational Zika, RSV, and HIV vaccines.

The ENSEMBLE data demonstrated that Johnson & Johnson’s single-dose COVID-19 vaccine was 85% effective against severe/critical disease. Additionally, the trial met its co-primary endpoints of protecting against moderate to severe COVID-19 at 14 and 28 days after vaccination, achieving 67% efficacy at 14 days after vaccination; and 66%  at 28 days after vaccination, with prevention against COVID-19-related hospitalization and death across all participants (N=44,325). Protection was generally consistent across race, age groups, including adults over 60 years of age (N=14,672), and those with and without comorbidities.

The Janssen COVID-19 vaccine has been authorized by FDA through an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID-19.

The Johnson & Johnson COVID-19 single-dose vaccine is compatible with standard vaccine storage and distribution channels with ease of delivery to remote areas. The vaccine is estimated to remain stable for two years at -20°C, and three months at 2 to 8°C.

The FDA EUA Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and full EUA Prescribing Information are available at: www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf.